Edition:
United Kingdom

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

1.93USD
13 Nov 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.93
Open
$1.96
Day's High
$1.99
Day's Low
$1.77
Volume
228,083
Avg. Vol
244,056
52-wk High
$15.00
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Achaogen Reports Q2 Loss Per Share Of $1.20
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Achaogen Inc ::ACHAOGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.20.Q2 EARNINGS PER SHARE VIEW $-0.92 -- THOMSON REUTERS I/B/E/S.QTRLY CONTRACT REVENUE $2.6 MILLION VERSUS $1.3 MILLION.ACHAOGEN - AT JUNE 30, 2018, HAD $100.5 MILLION IN UNRESTRICTED CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS COMPARED TO $164.8 MILLION AT DEC 31, 2017.  Full Article

Achaogen Announces Strategic Update
Thursday, 26 Jul 2018 

July 26 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES STRATEGIC UPDATE TO ALIGN OPERATIONS WITH COMMERCIAL AND CLINICAL DEVELOPMENT PRIORITIES.ACHAOGEN INC - - COMMERCIAL AND MEDICAL AFFAIRS TEAMS UNCHANGED BY RESTRUCTURING AS COMPANY EXECUTES ON U.S. COMMERCIAL LAUNCH OF ZEMDRI.ACHAOGEN - ESTIMATES RESTRUCTURING WILL RESULT IN ELIMINATION OF ABOUT 80 POSITIONS, OR ABOUT 28 PERCENT, OF CO'S WORKFORCE.ACHAOGEN INC - ESTIMATES ONE-TIME EMPLOYEE SEVERANCE AND BENEFITS CHARGE OF APPROXIMATELY $6.0M IN Q3 OF 2018.ACHAOGEN INC - COMPANY WILL ALSO RESTRUCTURE ACHAOGEN EXECUTIVE MANAGEMENT TEAM.ACHAOGEN INC - ZERYN SARPANGAL WILL ASSUME ROLE OF CHIEF FINANCIAL OFFICER ON OCTOBER 1, 2018.  Full Article

Achaogen Says Zemdritm Approved By FDA For Treatment Of Adults With Complicated Urinary Tract Infections
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Achaogen Inc ::ZEMDRITM (PLAZOMICIN) APPROVED BY FDA FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI).ACHAOGEN INC - REGARDING POTENTIAL INDICATION FOR PLAZOMICIN FOR TREATMENT OF BLOODSTREAM INFECTION (BSI), FDA ISSUED A COMPLETE RESPONSE LETTER.ACHAOGEN INC - CRL STATES THAT CARE STUDY DOES NOT PROVIDE SUBSTANTIAL EVIDENCE OF EFFECTIVENESS OF PLAZOMICIN FOR TREATMENT OF BSI.ACHAOGEN INC - INTENDS TO MEET WITH FDA TO DETERMINE WHETHER THERE IS A FEASIBLE RESOLUTION TO ADDRESS CRL.  Full Article

Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS.ACHAOGEN - INTENDS TO SUBMIT APPLICATION FOR MARKETING AUTHORIZATION FOR PLAZOMICIN IN EUROPEAN UNION IN 2018.  Full Article

Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST CLINICAL TRIAL OF ORALLY-ADMINISTERED ANTIBACTERIAL CANDIDATE C-SCAPE.ACHAOGEN INC - C-SCAPE WAS WELL TOLERATED ACROSS ALL DOSES STUDIED IN PHASE 1 TRIAL.ACHAOGEN INC - CONTINUE TO PLAN FOR PHASE 3 IN 2018.  Full Article

Achaogen Appoints Blake Wise Chief Executive Officer
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Achaogen Inc ::ACHAOGEN APPOINTS BLAKE WISE CHIEF EXECUTIVE OFFICER.ACHAOGEN INC - KENNETH HILLAN TO BECOME PRESIDENT, RESEARCH AND DEVELOPMENT.ACHAOGEN INC - BLAKE WISE WILL SUCCEED KENNETH HILLAN, AS CHIEF EXECUTIVE OFFICER EFFECTIVE JANUARY 1, 2018.  Full Article

Achaogen reports Q3 loss per share $0.85
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Achaogen Inc ::Achaogen reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.85.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Achaogen - ‍unrestricted cash, cash equivalents and short-term investments totaled $199.4 million at Sept 30, 2017 compared to $145.9 million at Dec 31, 2016​.  Full Article

Achaogen submits Plazomicin new drug application to FDA
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Achaogen Inc :Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections.Achaogen Inc - co also intends to submit an application for registration of Plazomicin​ in European Union in 2018.  Full Article

REFILE-UPDATE 2-FDA knocks back Achaogen's drug for bloodstream infection

June 26 The U.S. Food and Drug Administration cleared Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, but shares slumped 25 percent as the drug failed to win approval for treating bloodstream infections.